Facebook Instagram Linkedin Youtube
Home Search

combigene - search results

If you're not happy with the results, please do another search
CombiGene implements cost savings

CombiGene implements cost savings

CombiGene's CEO: “I am looking forward to meeting more potential partners”

CombiGene’s CEO: “I am looking forward to meeting more potential partners”

Continued focus on new licensing deals for CombiGene

CombiGene positive to new license agreement for CG01

Dicot has completed recruitement

She is CombiGene’s new CSO

CombiGene's pain programme takes important steps forward

CombiGene’s pain programme takes important steps forward

CombiGene’s CEO comments on the patent approvals in Australia and India

Comments from Orphazyme on the investment in CombiGene

Comments from Orphazyme on the investment in CombiGene

CombiGene comments on the discontinued CGT2 project

CombiGene: "We continue to believe in the epilepsy project CG01"

CombiGene: “We continue to believe in the epilepsy project CG01”

CombiGene comments on Eurostars funding

CombiGene focuses on the pain project

CombiGene focuses on the pain project

CombiGene has choosen CRO for the pain project

CombiGene has chosen CRO for the pain project

All sessions from BioStock Life Science Fall Summit 2023

Panel at BioStock Life Science Fall Summit 2023

Video from day 2 of BioStock Life Science Fall Summit 2023

CombiGenes vd om det avslutade Spark-avtalet

CombiGene’s CEO on the terminated collaboration with Spark

Intervjubanner_BIMSeptember2023

Watch the interviews from BioStock Investor Meeting!

Companypresentations_BIM2023Sept

Watch the presentations from BioStock Investor Meeting!

CombiGene welcomes AmbioPharm as CDMO in pain project

CombiGene welcomes AmbioPharm as CDMO in pain project

CombiGene’s new CEO talks about his visions for the company

CombiGene Q2 highlights and insights

CombiGene’s CEO gives a status update

CombiGene's CEO on the participation at BIO2023 in Boston

CombiGene’s CEO on the participation at BIO2023 in Boston

Aptahem's CEO comments on Q2 and looks ahead

Prominent role for CombiGene in newly established national ATMP collaboration

Zyneyro's CEO on the collaboration with CombiGene

Zyneyro’s CEO on the collaboration with CombiGene

CombiGenes vd Jan Nilsson i BioStocks tv-studio i Sotckholm

Status update from CombiGene’s CEO

CombiGene-epilepsi

Article about CombiGene’s epilepsy project published in Gene Therapy

BioStock Investor Meeting September 2023

BioStock Life Science Summit 2023

CombiGene

CombiGene’s pain project receives new scientific support

BioStock Life Science Summit 2023

Jan Nilsson, vd CombiGene

CombiGene´s CEO provides an operational update

Chronic pain in focus for CombiGene´s new collaboration

genterapi vid allvarlig hudsjukdom

Progress with a new gene therapy in severe skin disease

Combigene FDA approval Hemgenix

CombiGene’s CEO on the FDA approval of Hemgenix

CombiGene Q3 2022

CombiGene’s CEO on the favourable position

CombiGene

CombiGene’s new COO wants to be involved in building a large...

CombiGene focuses on further in-licensing

EU gene therapy approval positive for CombiGene

BioMarin’s gene therapy treatment receives EU approval

CombiGene comments on positive news for Bluebird

Cominie

CombiGene’s new project manager on a broadened pipeline

CombiGene

CombiGene’s Chairman of the Board comments on the future

CombiGene strives for a broader pipeline

CombiGene strives for a broader pipeline

CombiGene’s CEO gives business development update

CombiGene

CombiGene sails with tailwinds

CombiGene’s CEO about the path to the first clinical trial

CombiGene

CombiGene gears up for clinical studies and expanded pipeline

CombiGene are looking for broader opportunities

CombiGene’s scientific founders on the agreement with Spark

CombiGene strikes deal with Spark Therapeutics

CombiGene comments the international patent application

CombiGene’s CEO on this summer’s news

CombiGene gears up in epilepsy project

CombiGene’s new Chairman on visions for the future

CombiGene’s new agreement important for future clinical studies

CombiGene one step closer to clinical trials

Aptahem’s founder is back – now as Chairman of the Board

Bayer acquires gene therapy company AskBio in billion-dollar deal

CombiGene comments the final preclinical steps

CombiGene om den första in vivo-studien i lipodystrofiprojektet CGT2

12Page 1 of 2
© BioStock 2024